002317 众生药业
已收盘 11-06 15:00:00
资讯
新帖
简况
研报掘金｜浙商证券：维持众生药业“买入”评级，创新药逐步形成第二增长曲线
格隆汇 · 11-06 15:46
研报掘金｜浙商证券：维持众生药业“买入”评级，创新药逐步形成第二增长曲线
众生药业（002317）11月4日主力资金净买入1.38亿元
证券之星 · 11-05 09:12
众生药业（002317）11月4日主力资金净买入1.38亿元
众生药业涨9.99%，开源证券二个月前给出“买入”评级
证券之星 · 11-04
众生药业涨9.99%，开源证券二个月前给出“买入”评级
异动快报：众生药业（002317）11月4日13点58分触及涨停板
证券之星 · 11-04
异动快报：众生药业（002317）11月4日13点58分触及涨停板
股市必读：众生药业（002317）11月3日收盘跌5%，主力净流出2838.27万元
证券之星 · 11-04
股市必读：众生药业（002317）11月3日收盘跌5%，主力净流出2838.27万元
众生药业：适当时依法合规综合运用资本市场工具
证券之星 · 11-03
众生药业：适当时依法合规综合运用资本市场工具
众生药业：公司始终重视药品的国外市场机会
证券之星 · 11-03
众生药业：公司始终重视药品的国外市场机会
众生药业：RAY1225注射液III期临床试验获顶线分析数据
证券之星 · 11-03
众生药业：RAY1225注射液III期临床试验获顶线分析数据
众生药业涨6.22%，开源证券二个月前给出“买入”评级
证券之星 · 11-02
众生药业涨6.22%，开源证券二个月前给出“买入”评级
众生药业前三季营收、净利双降，创新药收入尚难对冲传统业务收缩
蓝鲸财经 · 11-02
众生药业前三季营收、净利双降，创新药收入尚难对冲传统业务收缩
众生药业(002317)9月30日股东户数5.81万户，较上期减少15.84%
证券之星 · 10-30
众生药业(002317)9月30日股东户数5.81万户，较上期减少15.84%
众生药业：昂拉地韦片是全球首个靶向甲型流感病毒RNA聚合酶PB2亚基的口服抗流感药物
证券之星 · 10-30
众生药业：昂拉地韦片是全球首个靶向甲型流感病毒RNA聚合酶PB2亚基的口服抗流感药物
众生药业：产能充足，能够灵活匹配市场需求
证券之星 · 10-30
众生药业：产能充足，能够灵活匹配市场需求
众生药业：公司将积极推进与监管部门的沟通，推进ZSP1601片III期临床试验
证券之星 · 10-30
众生药业：公司将积极推进与监管部门的沟通，推进ZSP1601片III期临床试验
图解众生药业三季报：第三季度单季净利润同比增长3.95%
证券之星 · 10-30
图解众生药业三季报：第三季度单季净利润同比增长3.95%
股市必读：众生药业新发布《关于全资子公司获得精氨酸布洛芬化学原料药上市申请批准通知书的公告》
证券之星 · 10-26
股市必读：众生药业新发布《关于全资子公司获得精氨酸布洛芬化学原料药上市申请批准通知书的公告》
股市必读：众生药业新发布《关于全资子公司获得精氨酸布洛芬化学原料药上市申请批准通知书的公告》
证券之星 · 10-23
股市必读：众生药业新发布《关于全资子公司获得精氨酸布洛芬化学原料药上市申请批准通知书的公告》
众生药业：签订协议时RAY1225注射液尚未获得上市批准
证券之星 · 10-22
众生药业：签订协议时RAY1225注射液尚未获得上市批准
众生药业：RAY1225注射液III期临床试验REBUILDING-2获顶线分析数据
证券之星 · 10-22
众生药业：RAY1225注射液III期临床试验REBUILDING-2获顶线分析数据
众生药业：公司坚持谨慎投资的原则
证券之星 · 10-20
众生药业：公司坚持谨慎投资的原则
加载更多
公司概况
公司名称：
广东众生药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-12-11
主营业务：
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是中成药、化学药、原料药及中间体、中药材及中药饮片。
发行价格：
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":24.89,"timestamp":1793948616000,"preClose":25.14,"halted":0,"volume":17977404,"delay":0,"changeRate":-0.0099,"floatShares":768000000,"shares":850000000,"eps":0.2374,"marketStatus":"已收盘","change":-0.25,"latestTime":"11-06 15:00:00","open":24.5,"high":25.06,"low":24.3,"amount":446000000,"amplitude":0.0302,"askPrice":24.9,"askSize":349,"bidPrice":24.89,"bidSize":725,"shortable":0,"etf":0,"ttmEps":0.2374,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":25.14,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":27.65,"lowLimit":22.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":5.25,"roa":"--","peRate":104.844145,"roe":"4.33%","epsLYR":0.33,"committee":-0.098249,"marketValue":21155000000,"turnoverRate":0.0234,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-09。","floatMarketCap":19116000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2681858505","title":"研报掘金｜浙商证券：维持众生药业“买入”评级，创新药逐步形成第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2681858505","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681858505?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:46","pubTimestamp":1793951210,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","159992","601878","BK0077","BK0188","002317","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681427090","title":"众生药业（002317）11月4日主力资金净买入1.38亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681427090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681427090?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:12","pubTimestamp":1793841149,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，众生药业报收于24.44元，上涨9.99%，涨停，换手率4.64%，成交量35.65万手，成交额8.31亿元。近5日资金流向一览见下表：众生药业融资融券信息显示，融资方面，当日融资买入3486.12万元，融资偿还3810.91万元，融资净偿还324.78万元。众生药业主营业务：药品研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500010770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","002317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680394460","title":"众生药业涨9.99%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680394460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680394460?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:34","pubTimestamp":1793784886,"startTime":"0","endTime":"0","summary":"今日众生药业（002317）涨9.99%，收盘报24.44元。2026年8月27日，开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告：创新管线稳步推进，ZSP1601临床IIb期数据超预期》，该研报对众生药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.6%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为信达证券的唐爱金、贺鑫。众生药业（002317）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680089441","title":"异动快报：众生药业（002317）11月4日13点58分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2680089441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680089441?lang=zh_cn&edition=full","pubTime":"2026-11-04 14:01","pubTimestamp":1793772065,"startTime":"0","endTime":"0","summary":"证券之星11月4日盘中消息，13点58分众生药业（002317）触及涨停板。其所属行业中药目前上涨。领涨股为桂林三金。该股为减肥药，创新药，化学原料药概念热股，当日减肥药概念上涨3.76%，创新药概念上涨3.7%，化学原料药概念上涨2.14%。11月3日的资金流向数据方面，主力资金净流出2838.27万元，占总成交额5.24%，游资资金净流出621.86万元，占总成交额1.15%，散户资金净流入3460.13万元，占总成交额6.39%。近5日资金流向一览见下表：众生药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400022089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680754937","title":"股市必读：众生药业（002317）11月3日收盘跌5%，主力净流出2838.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680754937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680754937?lang=zh_cn&edition=full","pubTime":"2026-11-04 01:04","pubTimestamp":1793725461,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，众生药业报收于22.22元，下跌5.0%，换手率3.13%，成交量24.04万手，成交额5.41亿元。交易信息汇总股价提醒11月3日众生药业收盘报22.22元，跌5%，当日成交5.41亿元。前10个交易日主力资金累计净流出3.45亿元，股价累计下跌5%；融资余额减少4770.17万元，融券余量减少4.25万股。近90天内7家机构给出评级，买入评级5家，增持评级2家；机构目标均价为34.18元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400002170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680197797","title":"众生药业：适当时依法合规综合运用资本市场工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2680197797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680197797?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:06","pubTimestamp":1793667970,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)11月02日在投资者关系平台上答复投资者关心的问题。投资者提问：强烈建议公司回购股票众生药业回复：感谢您对公司的建议！在严格遵守证券法等相关规定的前提下，公司将继续以提高经营质量为基础，持续完善公司治理，适当时依法合规综合运用资本市场工具和运作方式，拓展业务规模，逐步提高经营业绩，加强与投资者沟通，持续为股东创造更大价值。公司未来如有相关计划，将严格按照相关规则及要求履行决策程序和信息披露义务。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300012166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680679719","title":"众生药业：公司始终重视药品的国外市场机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2680679719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680679719?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:06","pubTimestamp":1793667969,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)11月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的RAY1225三期试验数据已经出来了，海外BD有没有公司沟通中啊？众生药业回复：您好！公司始终重视药品的国外市场机会，持续看好药品海外市场广阔机遇与增长空间。公司立足自身产品优势与研发实力，坚持稳健布局、审慎推进的原则，适时拓展海外市场，加快国际化推进步伐。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300012163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680797911","title":"众生药业：RAY1225注射液III期临床试验获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2680797911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680797911?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:03","pubTimestamp":1793667791,"startTime":"0","endTime":"0","summary":"公司自主研发的一类创新多肽药物RAY1225注射液在超重或肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验已获得顶线分析数据，初步结果表明，RAY1225注射液在中国成人肥胖/超重参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。另外，RAY1225注射液用于治疗2型糖尿病参与者的III期临床试验正在积极推进中。有关RAY1225注射液的进展情况请公司公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300012067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680737758","title":"众生药业涨6.22%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680737758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680737758?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:20","pubTimestamp":1793611251,"startTime":"0","endTime":"0","summary":"今日众生药业（002317）涨6.22%，收盘报23.39元。2026年8月27日，开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告：创新管线稳步推进，ZSP1601临床IIb期数据超预期》，该研报对众生药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.6%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为信达证券的唐爱金、贺鑫。众生药业（002317）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200025004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680732014","title":"众生药业前三季营收、净利双降，创新药收入尚难对冲传统业务收缩","url":"https://stock-news.laohu8.com/highlight/detail?id=2680732014","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680732014?lang=zh_cn&edition=full","pubTime":"2026-11-02 17:01","pubTimestamp":1793610109,"startTime":"0","endTime":"0","summary":"但从今年三季报的营收降幅来看，以量补价的完全对冲仍需时间。这意味着众生药业所处的政策环境并非阶段性收紧。从三季报的财务数据看，众生药业传统业务调整并未结束，创新药的收入贡献仍不足以改变整体营收下行的方向，在后续管线面临强竞争的环境下，转型成效还需持续观察。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1793610027686285506","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["06978","159992","MEDX","LNGR","002317","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213452","title":"众生药业(002317)9月30日股东户数5.81万户，较上期减少15.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213452","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213452?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:20","pubTimestamp":1793359246,"startTime":"0","endTime":"0","summary":"证券之星消息，近日众生药业披露，截至2026年9月30日公司股东户数为5.81万户，较6月30日减少1.09万户，减幅为15.84%。在中药行业个股中，众生药业股东户数高于行业平均水平，截至9月30日，中药行业平均股东户数为5.33万户。从股价来看，2026年6月30日至2026年9月30日，众生药业区间跌幅为2.2%，在此期间股东户数减少1.09万户，减幅为15.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000047469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679250436","title":"众生药业：昂拉地韦片是全球首个靶向甲型流感病毒RNA聚合酶PB2亚基的口服抗流感药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2679250436","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679250436?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:36","pubTimestamp":1793331372,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：今年流行的是甲流。公司的昂拉地韦是对甲流有效果，还是对乙流有效果？众生药业回复：您好！公司自主研发的一类创新药物昂拉地韦片（商品名：安睿威）是全球首个靶向甲型流感病毒RNA聚合酶PB2亚基的口服抗流感药物，适用于成人单纯性甲型流感患者的治疗，具有快速、强效、低耐药等特点，能够快速缓解全身流感症状、强效抗流感病毒，兼具低耐药性。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000024576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679425010","title":"众生药业：产能充足，能够灵活匹配市场需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2679425010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679425010?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:36","pubTimestamp":1793331371,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：今年甲流爆发，比以往的时候来得更早一些，公司的甲流特效药昂拉地韦销量如何？生产能跟上吗？众生药业回复：您好！公司密切关注疾病动态情况，积极做好药品生产和销售工作。公司拥有相对完整的产业链体系，拥有昂拉地韦原料、片剂的批文，保障原料药的供应质量与成本控制，具有原料制剂一体化竞争优势，产能充足，能够灵活匹配市场需求。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000024572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679250192","title":"众生药业：公司将积极推进与监管部门的沟通，推进ZSP1601片III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2679250192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679250192?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:36","pubTimestamp":1793331371,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司的ZSP1601片III期临床试验还没有开始吗？获得3期临床试验批件了吗？众生药业回复：您好！ZSP1601片已被国家药品监督管理局药品审评中心（CDE）纳入突破性治疗药物程序， CDE对纳入突破性治疗药物程序的药物优先配置资源进行沟通交流，加强指导并促进药物研发。公司将积极推进与监管部门的沟通，推进ZSP1601片III期临床试验。有关ZSP1601片的具体进展请以公司公告为准。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000024574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679746234","title":"图解众生药业三季报：第三季度单季净利润同比增长3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679746234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679746234?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:12","pubTimestamp":1793308334,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业2026年三季报显示，前三季度公司主营收入14.68亿元，同比下降22.28%；归母净利润1.77亿元，同比下降29.53%；扣非净利润1.84亿元，同比下降25.12%；其中2026年第三季度，公司单季度主营收入4.68亿元，同比下降20.62%；单季度归母净利润6515.7万元，同比上升3.95%；单季度扣非净利润6311.56万元，同比上升6.92%；负债率18.76%，投资收益889.54万元，财务费用-261.83万元，毛利率55.27%。财报数据概要请见下图:本文数据来源于众生药业2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000006476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678357241","title":"股市必读：众生药业新发布《关于全资子公司获得精氨酸布洛芬化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678357241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678357241?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:25","pubTimestamp":1792949112,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司获精氨酸布洛芬化学原料药上市申请批准通知书，登记号Y20250000480，审批结论为符合药品注册有关要求，批准注册。精氨酸布洛芬为布洛芬精氨酸盐，具有镇痛、解热和抗炎作用，适用于牙痛、痛经、创伤性疼痛、关节韧带痛、背痛、头痛、神经痛及流感发热等。上述事项不会对公司当期经营业绩产生重大影响。药品销售受政策、市场环境等因素影响，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677960759","title":"股市必读：众生药业新发布《关于全资子公司获得精氨酸布洛芬化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677960759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677960759?lang=zh_cn&edition=full","pubTime":"2026-10-23 01:28","pubTimestamp":1792690089,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司获精氨酸布洛芬化学原料药上市申请批准，登记号Y20250000480，审批结论为符合药品注册有关要求，批准注册。公司控股子公司众生睿创与齐鲁制药签署《许可协议》，众生睿创授权齐鲁制药在中国地区内对RAY1225注射液进行生产与商业化销售，是公司推动创新药平台建设与后续新药上市商业化的重要举措。公司将积极与药监部门沟通，争取早日完成申报药物上市，为广大患者提供更多治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300001581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677965932","title":"众生药业：签订协议时RAY1225注射液尚未获得上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2677965932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677965932?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:48","pubTimestamp":1792673311,"startTime":"0","endTime":"0","summary":"公司控股子公司众生睿创与齐鲁制药签署《许可协议》，众生睿创授权齐鲁制药在中国地区内对RAY1225注射液进行生产与商业化销售，是公司推动创新药平台建设与后续新药上市商业化的重要举措。公司已收到上述《许可协议》首付款20,000万元，结合RAY1225注射液的研发进度、企业会计准则等相关规定以及协议约定，签订协议时，RAY1225注射液尚未获得上市批准，因此公司未对已收取的首付款确认收入，后续满足收入确认条件后，会依规计入对应的报告期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200039738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677989968","title":"众生药业：RAY1225注射液III期临床试验REBUILDING-2获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2677989968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677989968?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:54","pubTimestamp":1792630445,"startTime":"0","endTime":"0","summary":"公司自主研发的一类创新多肽药物RAY1225注射液在超重或肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的III期临床试验已获得顶线分析数据，初步结果表明，RAY1225注射液在中国成人肥胖/超重参与者中表现出积极的疗效和良好的安全性，试验结果理想，达到预期目的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200007356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676957446","title":"众生药业：公司坚持谨慎投资的原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2676957446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676957446?lang=zh_cn&edition=full","pubTime":"2026-10-20 20:48","pubTimestamp":1792500492,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业10月19日在投资者关系平台上答复投资者关心的问题。公司坚持谨慎投资的原则，在确保公司正常经营、不影响公司募集资金安全和募集资金投资计划正常进行的前提下，通过对暂时闲置的募集资金进行现金管理及自有资金进行委托理财，有利于提高公司资金的使用效率和现金资产的收益，进一步提升公司整体业绩水平，符合公司和全体股东利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000034302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794093216332,"stockEarnings":[{"period":"1week","weight":0.1303},{"period":"1month","weight":0.0358},{"period":"3month","weight":-0.1291},{"period":"6month","weight":0.114},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.323}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"58101人(较上一季度减少15.84%)","perCapita":"13218股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是中成药、化学药、原料药及中间体、中药材及中药饮片。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}